Literature DB >> 15829505

Loss of wild-type huntingtin influences motor dysfunction and survival in the YAC128 mouse model of Huntington disease.

Jeremy M Van Raamsdonk1, Jacqueline Pearson, Daniel A Rogers, Nagat Bissada, A Wayne Vogl, Michael R Hayden, Blair R Leavitt.   

Abstract

Huntington disease (HD) is an adult-onset neurodegenerative disease caused by a toxic gain of function in the huntingtin (htt) protein. The contribution of wild-type htt function to the pathogenesis of HD is currently uncertain. To assess the role of wild-type htt in HD, we generated YAC128 mice that do not express wild-type htt (YAC128-/-) but express the same amount of mutant htt as normal YAC128 mice (YAC128+/+). YAC128-/- mice perform worse than YAC128+/+ mice in the rotarod test of motor coordination (P = 0.001) and are hypoactive compared with YAC128+/+ mice at 2 months (P = 0.003). Striatal neuropathology was not clearly worse in YAC128-/- mice compared with YAC128+/+ mice. There was no significant effect of decreased wild-type htt on striatal volume, neuronal counts or DARPP-32 expression but a modest worsening of striatal neuronal atrophy was evident (6%, P = 0.03). The testis of YAC128+/+ mice showed atrophy and degeneration, which was markedly worsened in the absence of wild-type htt (P = 0.001). YAC128+/+ mice also showed a male specific deficit in survival compared with WT mice which was exacerbated by the loss of wild-type htt (12-month-male survival, P < 0.001). Overall, we demonstrate that the loss of wild-type htt influences motor dysfunction, hyperkinesia, testicular degeneration and impaired lifespan in YAC128 mice. The mild effect of wild-type htt on striatal phenotypes in YAC128 mice suggests that the characteristic striatal neuropathology in HD is caused primarily by the toxicity of mutant htt and that replacement of wild-type htt will not be an adequate treatment for HD.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15829505     DOI: 10.1093/hmg/ddi147

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  48 in total

1.  Differential electrophysiological changes in striatal output neurons in Huntington's disease.

Authors:  Véronique M André; Carlos Cepeda; Yvette E Fisher; My Huynh; Nora Bardakjian; Sumedha Singh; X William Yang; Michael S Levine
Journal:  J Neurosci       Date:  2011-01-26       Impact factor: 6.167

2.  Loss of beta-III spectrin leads to Purkinje cell dysfunction recapitulating the behavior and neuropathology of spinocerebellar ataxia type 5 in humans.

Authors:  Emma M Perkins; Yvonne L Clarkson; Nancy Sabatier; David M Longhurst; Christopher P Millward; Jennifer Jack; Junko Toraiwa; Mitsunori Watanabe; Jeffrey D Rothstein; Alastair R Lyndon; David J A Wyllie; Mayank B Dutia; Mandy Jackson
Journal:  J Neurosci       Date:  2010-04-07       Impact factor: 6.167

Review 3.  Sexuality in Huntington's disease.

Authors:  Eva Z Schmidt; Raphael M Bonelli
Journal:  Wien Med Wochenschr       Date:  2008

4.  A SNP in the HTT promoter alters NF-κB binding and is a bidirectional genetic modifier of Huntington disease.

Authors:  Kristina Bečanović; Anne Nørremølle; Scott J Neal; Chris Kay; Jennifer A Collins; David Arenillas; Tobias Lilja; Giulia Gaudenzi; Shiana Manoharan; Crystal N Doty; Jessalyn Beck; Nayana Lahiri; Elodie Portales-Casamar; Simon C Warby; Colúm Connolly; Rebecca A G De Souza; Sarah J Tabrizi; Ola Hermanson; Douglas R Langbehn; Michael R Hayden; Wyeth W Wasserman; Blair R Leavitt
Journal:  Nat Neurosci       Date:  2015-05-04       Impact factor: 24.884

Review 5.  Animal models of human genetic diseases: do they need to be faithful to be useful?

Authors:  Jean-Louis Guénet
Journal:  Mol Genet Genomics       Date:  2011-05-06       Impact factor: 3.291

Review 6.  Huntington's disease and the striatal medium spiny neuron: cell-autonomous and non-cell-autonomous mechanisms of disease.

Authors:  Michelle E Ehrlich
Journal:  Neurotherapeutics       Date:  2012-04       Impact factor: 7.620

Review 7.  Chemical inducers of autophagy that enhance the clearance of mutant proteins in neurodegenerative diseases.

Authors:  Maurizio Renna; Maria Jimenez-Sanchez; Sovan Sarkar; David C Rubinsztein
Journal:  J Biol Chem       Date:  2010-02-10       Impact factor: 5.157

8.  Responses to environmental enrichment differ with sex and genotype in a transgenic mouse model of Huntington's disease.

Authors:  Nigel I Wood; Valentina Carta; Stefan Milde; Elizabeth A Skillings; Catherine J McAllister; Y L Mabel Ang; Alasdair Duguid; Nadeev Wijesuriya; Samira Mohd Afzal; Joe X Fernandes; T W Leong; A Jennifer Morton; Jennifer Morton
Journal:  PLoS One       Date:  2010-02-12       Impact factor: 3.240

9.  Partial loss of ataxin-1 function contributes to transcriptional dysregulation in spinocerebellar ataxia type 1 pathogenesis.

Authors:  Juan Crespo-Barreto; John D Fryer; Chad A Shaw; Harry T Orr; Huda Y Zoghbi
Journal:  PLoS Genet       Date:  2010-07-08       Impact factor: 5.917

10.  Design of RNAi hairpins for mutation-specific silencing of ataxin-7 and correction of a SCA7 phenotype.

Authors:  Janine Scholefield; L Jacquie Greenberg; Marc S Weinberg; Patrick B Arbuthnot; Amr Abdelgany; Matthew J A Wood
Journal:  PLoS One       Date:  2009-09-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.